

Philip Morris International Inc.
Science and Technology Committee Charter

Membership

The Science and Technology Committee (the “Committee”) of the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company”) shall consist of at least three directors chosen by the Board. Based on the recommendation of the Nominating and Corporate Governance Committee, the Board annually shall elect the members and the Chair of the Committee at the Board’s organizational meeting following the Annual Meeting of Shareholders. The members of the Committee may be removed by the Board.

Purpose

The purpose of the Committee is to oversee the long-term product portfolio strategy of the Company, focusing on research and development of new products and services and improvements to existing products and services.

The Committee will oversee: (i) the research and development of the Company’s smoke-free products (“SFPs”), which is the term the Company primarily uses to refer to all of its products that are not combustible tobacco products, such as heat-not-burn, e-vapor, and oral nicotine; (ii) the development of the Company’s Wellness and Healthcare Portfolio, which describes the products that the Company will develop in through its inhaled therapeutics and wellness and healthcare operations; (iii) the timetable for market entry of new products; (iv) the Company’s overall research and development strategies, including those of the Company’s reduced-risk products, which is the term the Company uses to refer to SFPs that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing to smoke; and (v) quality systems with respect to the products that are manufactured and commercialized by the Company. The Committee will also monitor key legislative, regulatory and public policy issues and trends related to the research and development of the Company’s products and services as well as the premarket regulatory process of scientifically evaluating product performance and authorizing the sale of SFPs and Wellness and Healthcare products.

In furtherance of this purpose, the Committee will:

1. Review the overall research and development and innovation strategy of the Company and report to the Board regarding such review in order to help facilitate the Board’s oversight of the Company’s innovation strategy and goals;
2. Review the Company’s pipeline of innovative products, including existing and future SFPs and Wellness and Healthcare products, and associated benefits and risks such as product superiority, product reliability, and time to market;
3. Review the Company’s regulatory strategy and compliance programs as it relates to the development of products, as applicable;
4. Review the competitive landscape in terms of related external scientific research, discoveries and commercial developments and potential future innovations in SFPs and Wellness and Healthcare products, as appropriate;
5. Review the Company’s overall intellectual property (“IP”) strategies and its portfolio of patents and other IP;

6. Review and consider management's prioritization decisions regarding the allocation, deployment, utilization of and investment in the Company's scientific and development assets and product offerings;
7. Review management's decisions regarding acquiring or divesting scientific technology or otherwise investing in research or development programs;
8. Assist the Board with its oversight responsibility for enterprise risk management in areas affecting:
(a) the Company's research and development efforts, including the Company's risks related to innovation, IP and research related to SFPs and Wellness and Healthcare products, and (b) quality systems with respect to the products that are manufactured and commercialized by the Company, including risks related to product safety;
9. Assist, upon the request of the Compensation and Leadership Development Committee, in setting annual scientific performance goals and assessing achievement of such goals for the executives in the Company's Wellness and Healthcare business;
10. Annually review and assess the adequacy of this charter and recommend any proposed changes to the Board for approval, including changes concerning the structure and operations of the Committee;
11. Perform, at the direction of the Nominating and Corporate Governance Committee, an annual performance evaluation of the Committee and report to the Board on the results of such evaluation; and
12. Perform such other duties and responsibilities as are consistent with the purpose of the Committee and as the Board or the Committee shall deem appropriate.

Procedures

The Committee shall meet as often as it deems appropriate to carry out its responsibilities. A majority of the members of the Committee shall constitute a quorum. The Chair of the Committee, in consultation with the other Committee members, shall set meeting agendas. The Committee shall regularly report its actions and recommendations to the Board.

Management will present to the Committee a description of and estimated budget for any proposed significant research and/or product development project. The Committee will consider whether to recommend to the Board that it approve the project within the context of the Company's original budget and long-range plan. It will also consider from time to time whether to recommend to the Board that an ongoing project be terminated.

The Committee shall have the sole authority to retain and terminate any advisors to the Committee as the Committee may deem appropriate, including sole authority to approve related fees and terms of any advisors to the Committee that it retains. The Company shall provide for appropriate funding, as determined by the Committee, for payment of reasonable compensation to any consultant, counsel or adviser retained by the Committee.

The Committee may delegate its authority to subcommittees or the Chair of the Committee when it deems appropriate.

As approved by the Board of Directors on June 6, 2024.